Verition Fund Management
IMCR icon

Verition Fund Management’s Immunocore IMCR Stock Holding History

Verition Fund Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-23,755
Closed -$739K – 3360
2024
Q3 		$739K Buy
+23,755
New +$864K ﹤0.01% 2085
2023
Q1 		– Sell
-3,996
Closed -$228K – 2348
2022
Q4 		$228K Buy
+3,996
New +$225K ﹤0.01% 1669

Other funds holding IMCR

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Verition Fund Management's IMCR Position: Q4 2024 in Review

Verition Fund Management sold out of Immunocore (IMCR) in Q4 2024, closing a stake of 23,755 shares — an estimated $739K sold.

Verition Fund Management first reported a position in IMCR in Q4 2022 and held it in 2 quarters. The position peaked at $739K in Q3 2024. 115 funds tracked by Wall St. Rank hold IMCR as of Q4 2024.

  • Verition Fund Management reported no remaining Immunocore position as of Q4 2024 after selling out during the quarter.
  • Verition Fund Management sold 23,755 Immunocore shares in Q4 2024, an estimated $739K.
  • Verition Fund Management first reported a position in Immunocore in Q4 2022 and held it in 2 quarters.
  • Verition Fund Management's Immunocore position peaked at $739K in Q3 2024.
  • 115 funds tracked by Wall St. Rank held Immunocore as of Q4 2024.

Based on Verition Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.